BMS 833923

Drug Profile

BMS 833923

Alternative Names: BMS-833923; XL-139

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myeloid leukaemia
  • No development reported Gastrointestinal cancer; Multiple myeloma; Small cell lung cancer; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Canada (PO, Capsule)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (PO, Capsule)
  • 03 Mar 2016 No recent reports of development identified - Phase-I for Gastrointestinal cancer (Combination therapy, First-line therapy, Metastatic disease) in Netherlands, France, Canada, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top